Treatment patterns in hormone-sensitive metastatic prostate cancer: data from a referral hospital in Bogota, real-world evidence study

Introduction Treatment for hormone-sensitive metastatic prostate cancer (mHSPC) has evolved in recent years with the addition of multiple treatment intensification options associated with androgen deprivation therapies (ADT), which were previously considered the mainstay of treatment, Treatment intensification includes taxane-containing chemotherapy and therapies that target the androgen receptor axis-directed therapies (ARATs)1. During the past 7 years, […]